Trials / Not Yet Recruiting
Not Yet RecruitingNCT07100925
A Study of Tolododekin Alfa (ANK-101) in Renal Allograft Recipients With High Risk Cutaneous Squamous Cell Carcinoma
An Open-Label Study of Tolododekin Alfa (ANK-101) in Renal Allograft Recipients With Resectable, High-Risk Cutaneous Squamous Cell Carcinoma
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Ankyra Therapeutics, Inc · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
A study of tolododekin alfa (also known as ANK-101) administered prior to surgery in kidney transplant participants that also have high-risk cutaneous squamous cell carcinoma (CSCC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | tolododekin alfa | IT administration of ANK-101 once every 3 weeks for 2 cycles, followed by surgical resection |
Timeline
- Start date
- 2025-12-15
- Primary completion
- 2030-06-01
- Completion
- 2030-12-01
- First posted
- 2025-08-03
- Last updated
- 2025-08-03
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07100925. Inclusion in this directory is not an endorsement.